AXSM Axsome Therapeutics Inc
Price (delayed)
$109.75
Market cap
$5.35B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.99
Enterprise value
$5.23B
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people
Highlights
AXSM's gross profit is up by 44% year-on-year and by 14% since the previous quarter
The revenue has grown by 43% YoY and by 14% from the previous quarter
The net income has contracted by 20% YoY but it has grown by 8% from the previous quarter
The EPS has contracted by 14% YoY but it has grown by 9% from the previous quarter
The equity has dropped by 70% year-on-year and by 39% since the previous quarter
The quick ratio has contracted by 42% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of AXSM
Market
Valuations
Earnings
Shares outstanding
48.77M
Market cap
$5.35B
Enterprise value
$5.23B
Price to earnings (P/E)
N/A
Price to book (P/B)
93.29
Price to sales (P/S)
13.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.56
Revenue
$385.69M
Gross profit
$352.39M
Operating income
-$280.56M
Net income
-$287.22M
EBIT
-$280.56M
EBITDA
-$271.22M
Free cash flow
-$128.68M
Per share
Balance sheet
Liquidity
EPS
-$5.99
EPS diluted
-$5.99
Free cash flow per share
-$2.69
Book value per share
$1.18
Revenue per share
$8.05
TBVPS
$10.63
Total assets
$568.5M
Total liabilities
$511.48M
Debt
$191.53M
Equity
$57.02M
Working capital
$254.96M
Debt to equity
3.36
Current ratio
2.11
Quick ratio
1.99
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
-70.3%
Gross margin
91.4%
Net margin
-74.5%
Operating margin
-72.7%
Return on assets
-51.7%
Return on equity
-289.5%
Return on invested capital
-161.8%
Return on capital employed
-82.9%
Return on sales
-72.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AXSM stock price
How has the Axsome Therapeutics stock price performed over time
Intraday
-1.72%
1 week
-7.9%
1 month
-13.95%
1 year
47.2%
YTD
29.71%
QTD
-5.9%
Financial performance
How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$385.69M
Gross profit
$352.39M
Operating income
-$280.56M
Net income
-$287.22M
Gross margin
91.4%
Net margin
-74.5%
AXSM's gross profit is up by 44% year-on-year and by 14% since the previous quarter
The revenue has grown by 43% YoY and by 14% from the previous quarter
The company's operating income fell by 21% YoY but it rose by 8% QoQ
The net income has contracted by 20% YoY but it has grown by 8% from the previous quarter
Growth
What is Axsome Therapeutics's growth rate over time
Valuation
What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
93.29
P/S
13.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.56
The EPS has contracted by 14% YoY but it has grown by 9% from the previous quarter
The P/B is 143% higher than the 5-year quarterly average of 39.0 and 109% higher than the last 4 quarters average of 45.4
The equity has dropped by 70% year-on-year and by 39% since the previous quarter
The revenue has grown by 43% YoY and by 14% from the previous quarter
The price to sales (P/S) is 8% higher than the last 4 quarters average of 12.9
Efficiency
How efficient is Axsome Therapeutics business performance
The ROE has plunged by 158% YoY and by 24% from the previous quarter
The ROS has grown by 20% from the previous quarter and by 15% YoY
AXSM's ROA is down by 18% YoY but it is up by 7% QoQ
The company's return on invested capital fell by 17% YoY but it rose by 4.6% QoQ
Dividends
What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AXSM.
Financial health
How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 11% more than its total liabilities
The quick ratio has contracted by 42% YoY and by 13% from the previous quarter
AXSM's current ratio is down by 42% year-on-year and by 14% since the previous quarter
The equity has dropped by 70% year-on-year and by 39% since the previous quarter
The debt to equity has soared by 63% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.